Organogenesis (ORGO) Cantor Global Healthcare Conference 2025 summary

Company background and leadership

• Founded in 1985 as a biotech spinoff from MIT, evolving from a single-product to a diversified wound care and surgical organization over 40 years.

• Leadership includes a CEO with 25 years at the company and a CFO with extensive diagnostics industry experience.

Regulatory and reimbursement environment

• Major changes in the Physician Fee Schedule (PFS) will standardize reimbursement across care sites, unbundle payments, and introduce tiered CMS classifications based on FDA status.

• The new model is expected to stabilize the market, eliminate financial incentives for product selection, and focus competition on clinical efficacy and service.

Product portfolio and innovation

• PMA products like Dermograft and TransCyte are positioned for growth, with manufacturing expansion in Rhode Island.

• Two new dehydrated products, including Vimatrix, launched in the second half and are gaining traction.

• The surgical and sports medicine segment grew 16% in Q2, driven by PuraPly and new launches like Signature Matrix.